| Project/Area Number |
21590151
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
YASUHARA Masato 東京医科歯科大学, 医学部・附属病院, 教授 (00127151)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | ニューキノロン系抗菌薬 / ガチフロキサシン / シベンゾリン / 血糖値異常 / ファーマコキネティックス / ファーマコダイナミックス / ペンタミジン / ファーマコキネティクス / 間接モデル / ファーマコキネテックス / 間モデル / インスリン |
|---|
| Research Abstract |
Gatifloxacin, a fluoroquinolone antibacterial agent, caused hypoglycemia in rats after i. v. administration by increasing the serum concentration of insulin. At higher serum concentration of gatifloxacin, it promoted histamine release, leading to an increased serum epinephrine concentration and hyperglycemia. Cibenzoline induced a rapid increase in the serum concentration of insulin. As the cibenzoline dose was increased, a greater hypoglycemic effect occurred. The time courses of serum concentrations of cibenzoline, insulin and glucose could be described by the pharmacokinetic and pharmacodynamic model developed.
|
